Hutchison China Meditech Limited Blocklisting Six Monthly Return (2982R)
June 29 2020 - 2:00AM
UK Regulatory
TIDMHCM
RNS Number : 2982R
Hutchison China Meditech Limited
29 June 2020
Blocklisting Six Monthly Return
London: Monday, June 29, 2020 : Hutchison China MediTech Limited
("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the
following blocklisting six monthly return:
1. Name of applicant: Hutchison China MediTech Limited
2. Name of scheme: (a) Share Option Scheme conditionally adopted
by Hutchison China MediTech Limited
in 2005 ("2005 HCML Share Option Scheme")
(b) Share Option Scheme conditionally adopted
by Hutchison China MediTech Limited
in 2015 ("2015 HCML Share Option Scheme")
3. Period of return: From December 29, 2019 to June 28, 2020
4. Balance under scheme (a) 2005 HCML Share Option Scheme: 1,738,910
from previous return: ordinary shares of US$0.1 each
(b) 2015 HCML Share Option Scheme: 23,130,970
ordinary shares of US$0.1 each
5. The amount by which (a) 2005 HCML Share Option Scheme: Nil
the block scheme has
been increased, if
the scheme has been
increased since the
date of the last return:
(b) 2015 HCML Share Option Scheme: Nil
6. Number of securities (a) 2005 HCML Share Option Scheme: Nil
issued/allotted under
scheme during period:
(b) 2015 HCML Share Option Scheme: Nil
7. Balance under scheme (a) 2005 HCML Share Option Scheme: 1,738,910
not yet issued/allotted ordinary shares of US$0.1 each
at end of the period:
(b) 2015 HCML Share Option Scheme: 23,130,970
ordinary shares of US$0.1 each
8. Number and class of 25,198,880 ordinary shares of US$0.1 each
securities originally admitted on June 17, 2019 ( to replace
listed and the date the Company's previous block admission
of admission: schemes following the Company's share subdivision
which took effect on May 30, 2019)
9. Total number of securities 690,574,765 ordinary shares of US$0.1 each
in issue at the end
of the period:
Name of contact: Christian Hogg
Address of contact: Level 18, The Metropolis Tower, 10 Metropolis
Drive, Hung Hom, Kowloon, Hong Kong
Telephone number of contact: +852 2121 8200
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical
company committed, over the past twenty years, to the discovery and
global development of targeted therapies and immunotherapies for
the treatment of cancer and immunological diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world and extensive commercial infrastructure in
its home market of China. For more information, please visit:
www.chi-med.com .
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BLRUWOARRKUNUUR
(END) Dow Jones Newswires
June 29, 2020 02:00 ET (06:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024